CM-272

CAT: 0804-HY-101925-01Size: 5 mgDry Ice: NoHazardous: No
CAT#:0804-HY-101925-01Size:5 mg
Selected
AVAILABILITY: InStock
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Product image 1
1 / 1
Description
CM-272 is a first-in-class, potent, selective, substrate-competitive and reversible dual G9a/DNA methyltransferases (DNMTs) inhibitor with antitumor activities. CM-272 inhibits G9a, DNMT1, DNMT3A, DNMT3B and GLP with IC50s of 8 nM, 382 nM, 85 nM, 1200 nM and 2 nM, respectively. CM-272 inhibits cell proliferation and promotes apoptosis, inducing IFN-stimulated genes and immunogenic cell death[1].
CAS Number
[1846570-31-7]
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Apoptosis; DNA Methyltransferase; Histone Methyltransferase
Type
Reference compound
Related Pathways
Apoptosis; Epigenetics
Applications
Cancer-programmed cell death
Field of Research
Cancer
Assay Protocol
https://www.medchemexpress.com/cm-272.html
Concentration
10mM
Purity
98.70
Solubility
DMSO : 125 mg/mL (ultrasonic)
Smiles
CN(CC1)CCC1NC2=CC(C3=CC=C(C)O3)=NC4=CC(OCCCN5CCCC5)=C(OC)C=C42
Molecular Formula
C28H38N4O3
Molecular Weight
478.63
Precautions
H302, H315, H319, H335
References & Citations
[1]San José-Enériz E, et al. Discovery of first-in-class reversible dual small molecule inhibitors against G9a and DNMTs in hematological malignancies. Nat Commun. 2017 May 26;8:15424.
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Isoform
DNMT1; DNMT3; EHMT1/GLP/KMT1D; EHMT2/G9a/KMT1C